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148Objective: Acute kidney injury after cardiac surgery with cardiopulmonary bypass is closely related to systemic
inflammatory reactions and oxidative stresses. Remote ischemic preconditioning is a systemic protective strategy
whereby brief limb ischemia confers systemic protection against prolonged ischemia and inflammatory reactions in
distant organs. This study investigated whether remote ischemic preconditioning provides systemic protective ef-
fect on kidneys that are not directly exposed to ischemia–reperfusion injury during complex valvular heart surgery.
Methods: Seventy-six adult patients undergoing complex valvular heart surgery were randomly assigned to
either remote ischemic preconditioning group (n ¼ 38) or control group (n ¼ 38). Remote ischemic precondi-
tioning consisted of 3 10-minute cycles of lower limb ischemia and reperfusion with an automated cuff inflator.
Primary end points were comparisons of biomarkers of renal injury including serum creatinine, cystatin C and
neutrophil gelatinase–associated lipocalin, and incidence of acute kidney injury. Secondary end points were
comparisons of myocardial enzyme release and pulmonary parameters.
Results: There were no significant differences in serum levels of biomarkers of renal injury between groups
throughout the study period. The incidence of acute kidney injury did not differ between groups. Creatine kinase
isoenzyme MB at 24 hours after surgery was lower, and intensive care unit stay was shorter in the remote ische-
mic preconditioning group than in the control group.
Conclusions: In patients undergoing complex valvular heart surgery, remote ischemic preconditioning did not
reduce degree of renal injury or incidence of acute kidney injury whereas it did reduce myocardial injury and
intensive care unit stay. (J Thorac Cardiovasc Surg 2011;142:148-54)Cardiac surgery with cardiopulmonary bypass (CPB) is in-
variably accompanied by systemic inflammatory response
and ischemia–reperfusion injury affecting multiple organs.
Although during CPB and cardioplegic arrest the kidneys
are under virtually continuous circulation, unlike the heart
and lungs, decreased renal perfusion along with ineffective
oxygen delivery system and high metabolic rate still make
the kidneys vulnerable to ischemic injury. In conjunction,
development of acute kidney injury (AKI) continues to be
a common and serious complication, especially after com-
plex valvular heart surgery requiring prolonged CPB.1-3
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stay, necessitating efforts to attenuate its development.4,5
Although the pathogenesis of AKI during CPB is com-
plex, involving hemodynamic, oxidative and inflammatory
mechanisms, remote ischemic preconditioning (RIPC) is
a systemic protective strategy, whereby brief limb ischemia
confers systemic protection against prolonged ischemia in
distant organs.6,7 RIPC’s effects are mediated through
either humoral mediators or the recruitment of a neuronal
pathway, with most evident beneficial effects observed on
the myocardium, which is exposed to actual ischemia–
reperfusion injury during CPB.8,9 Although the kidneys
are not directly exposed to ischemia–reperfusion injury,
RIPC could exert renal protection through its systemic
effect of attenuating the consequent activation of
inflammatory cascade and production of oxygen free
radicals.7 Evidence is limited, however, regarding the pro-
tective utility of limb RIPC against AKI in patients under-
going complex valvular heart surgery. We therefore
investigated, in a prospective and randomized controlled
trial, whether a limb RIPC protocol is effective in providing
renal protection in patients with normal preoperative renal
function undergoing complex valvular heart surgery.
MATERIALS AND METHODS
After approval of the institutional review board and procurement of
informed consent, we studied 76 adult patients scheduled for elective,ery c July 2011
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AKI ¼ acute kidney injury
CK-
MB
¼ creatine kinase isoenzyme MB
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
NGAL ¼ neutrophil gelatinase–associated
lipocalin
Qs/Qt ¼ Intrapulmonary shunt
RIPC ¼ remote ischemic preconditioning
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Mcomplex valvular heart surgery, which was defined as double-valve surgery,
combined valve and coronary artery bypass grafting procedures, Bentall op-
eration, combined mitral valve surgery and tricuspid annuloplasty or
reoperation between October 2008 and November 2009. We excluded pa-
tients older than 80 years and those with left main coronary artery disease
greater than 50%, hepatic or pulmonary disease, active infective endocar-
ditis, left ventricular ejection fraction less than 30%, myocardial infarction
within 3 weeks, preexisting renal dysfunction (serum creatinine level
>1.6 mg/dL for men and>1.4 mg/dL for women), or peripheral vascular
disease affecting the lower limbs. In addition, patients taking the antidia-
betic sulphonylurea glyburide (INN glibenclamide) or receiving nicorandil
drug therapy were excluded because these agents have been shown to abol-
ish preconditioning.10,11 Patients who required surgery for tricuspid valve
replacement or hypothermic circulatory arrest were also excluded.
After induction of anesthesia, patients were randomly assigned to either
the RIPC group (n¼ 38) or the control group (n¼ 38) by means of a com-
puterized randomization table. RIPC consisted of 3 10-minute cycles of
lower limb ischemia induced by an automated cuff-inflator placed on the
upper leg at an inflation pressure of 250mmHgwith an intervening 10min-
utes of reperfusion during which the cuff was deflated. Control patients had
a deflated cuff placed on the upper leg in place of RIPC application. Both
cardiac surgeon and attending anesthesiologist were blinded to treatment
allocation. There was at least a 10-minute interval between completion
of the RIPC protocol and initiation of CPB.
All preoperative cardiac medications except diuretics were continued
until the day of surgery. All patients received a standardized anestheticman-
agement. In the operating room, standard monitoring devices were applied.
Anesthesia was induced with intravenous midazolam (0.03–0.07 mg/kg),
sufentanil (1.5–3.0 mg/kg), and rocuronium bromide (0.9 mg/kg) andmain-
tainedwith sevoflurane (0.8%–1.5%) and continuous infusion of sufentanil
(0.5–1.5 mg/[kg $ h]). After intubation, the lungs were ventilated at a tidal
volume of 8 mL/kg, an inspiratory/expiratory time ratio of 1:2, and an
inspiratory pause of 10% of total inspiration time in 40% oxygen with
air and a positive end-expiratory pressure of 5 cm H2O. Respiratory rate
was adjusted between 8 and 12 breaths/min to maintain normocarbia.
All patients received standardized surgical and CPB management with
hemofiltration. CPB was instituted with a membrane oxygenator primed
with 1200mLof crystalloid solution, 200mLof 20%mannitol, and 100mL
of 20% albumin. Surgical procedures were performed with patients under
mild hypothermia (32C–33C). Acid–base management was done with
the a-stat method, and the target range for PaO2 was 200 to 300 mm Hg.
A nonpulsatile pumpflowwasmaintained at a rate of 2.0 to 2.5 L/[min $m2],
and blood cardioplegic solution was used. After the completion of the sur-
gical procedure and systemic rewarming, patients were weaned from CPB.
During the perioperative period, including CPB, mean arterial pressurewas
maintained between 60 and 80 mm Hg. For vasopressor and inotropic sup-
port, norepinephrine and milrinone were used, respectively. Milrinone was
used preferentially if the postbypass left ventricular ejection fraction wasThe Journal of Thoracic and Calower than 30%, in case of evidence of right ventricular dysfunction, and
in cases of pulmonary hypertension. Hemodynamic variables, including
cardiac index, and the need for vasoactive drugs or inotropes were recorded
15 minutes after tracheal intubation (baseline, T1), 15 minutes after sternal
closure (T2), and 12 and 24 hours after ICU arrival (T3 and T4). At the same
time points, arterial blood was sampled. Intrapulmonary shunt (Qs/Qt) was
measured at T1 and T2. Qs/Qt was determined by the formula: Qs/
Qt¼ (CcO2CaO2)/(CcO2CvO2), whereCcO2 represents capillary oxygen
content, calculated assuming that pulmonary capillary PO2 is equal to
alveolar PO2, CaO2 represents arterial oxygen content, and CvO2 represents
venous oxygen content.Oxygen contents in arterial andmixedvenous blood
were calculated with the equations CaO2¼ 1.36 $Hb $ SaO2þ0.0031 $ PaO2
and CvO2 ¼ 1.36 $ Hb $ SvO2þ0.0031 $ PvO2, where Hb represents hemo-
globin concentration (in grams per deciliter), SaO2 represents arterial oxy-
gen saturation, SvO2 represents venous oxygen saturation, and PvO2
represents venous PO2.
The threshold for transfusion of packed red blood cells was hematocrit
less than 20% during CPB or less than 25% after CPB. After heparin was
reversed, the blood from the CPB circuit was salvaged (cell salvage device)
and retransfused after sternal closure. Urinary output and all fluids (crystal-
loids, colloids, and blood products) administered to the patient were
recorded until the second postoperative day. Blood glucose levels were
strictly targeted between 80 and 150 mg/dL with insulin throughout the
study period.
All patientswere transferred to the ICUafter surgery,where they received
management according to institutional guidelines. Tracheal extubation was
performed when hemodynamic condition was stable and the patient had ad-
equate blood gas values while breathing spontaneously. Postoperative fluid
therapy was performed as needed to keep pulmonary capillary wedge pres-
sure between 10 and 14 mm Hg, cardiac index greater than 2 L/(min $ m2),
and urinary output greater than 0.5 mL/(kg $ h). Patients with urinary output
less than 30 mL/h despite volume correction and maintenance of adequate
cardiac and hemodynamic function were given intermittent doses of furose-
mide (5–40 mg every 3–4 hours). The durations of ventilation, stay in the
ICU, and postoperative hospitalization were recorded.
Biochemistry
Serum creatinine levels were determined at least twice daily during the
first 2 postoperative days and then daily during the hospital stay. Serum cys-
tatin C was assessed 1 day before surgery, at ICU arrival, and at 24 and 48
hours after surgery. Blood samples were collected for measurement of
plasma neutrophil gelatinase–associated lipocalin (NGAL) before induc-
tion of anesthesia, at ICU arrival, and 24 hours after surgery. Serum was
separated from blood by centrifugation and stored at70C until assay.
Plasma NGAL level was detected by using a commercially available
enzyme-linked immunosorbent assay kit (Human Lipocalin-2/NGAL Im-
munoassay; R&D Systems, Inc, Minneapolis, Minn) according to manu-
facturer instructions. Estimated glomerular filtration rate was calculated
by the Modification of Diet in Renal Disease formula as 186 $ (serum
creatinine level1.154) $ (age0.203) $ (0.742 for female patients).12 Creatine
kinase isoenzyme MB (CK-MB) was assessed 1 day before surgery and at
12 and 24 hours after surgery.
Study End Points
The primary end point was to compare the serum biomarkers of renal
injury and the incidence of AKI between groups. AKI was defined accord-
ing to the Acute Kidney Injury Network criteria as an increase in serum
creatinine level by either more than 50% or more than 0.3 mg/dL from
baselinewithin 48 hours after surgery.13 The secondary end point was com-
parison of serum CK-MB levels at 12 and 24 hours after surgery.
Statistical Analysis
Data were analyzed with SPSS version 14.0 statistical software (SPSS
Inc, an IBM Company, Chicago, Ill) and expressed as mean  SD orrdiovascular Surgery c Volume 142, Number 1 149
FIGURE 1. Diagram representing study cohort allocation.
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Mnumber of patients. In the preliminary trial of 18 patients, the highest serum
creatinine levels were 1.34  0.38 and 1.01  0.35 mg/dL in the control
and RIPC groups, respectively, within 48 hours after surgery. According
to a preliminary study, we calculated that 38 patients would be required
in each group for a 90% power to detect a 0.3-mg/dL difference in serum
creatinine level between the groups with SD of 0.4 mg/dL and a level of .05
with an independent t test. Data were compared between the groups with
the c2 test, Fisher’s Exact test, independent t test, or Mann–Whitney U
test as appropriate. For intragroup comparisons of variables against base-
line values, repeated measures analysis of variance followed by a post
hoc Dunnett test was used.RESULTS
One hundred nine patients were assessed for eligibility.
Five patents declined to participate. Twenty-eight patients
were excluded according to exclusion criteria. A total of 76
patients were randomly assigned (Figure 1). Patient charac-
teristics were similar between the groups (Table 1). No local
adverse effects related to the RIPC stimulus were observed.
The distributions of types of surgical procedures were
similar between groups. Mean durations of CPB and aortic
crossclamping and the numbers of patients with CPB last-
ing longer than 180 minutes were not different between
the groups (Table 2). Total amounts of fluid infused and uri-
nary outputs during the operation were similar between the150 The Journal of Thoracic and Cardiovascular Surggroups. The numbers of patients and total amount of packed
red blood cells transfused were similar between the groups
during the study period. Urinary output showed a trend to-
ward being higher during the first 24 hours after ICU admis-
sion in the RIPC group than in the control group (Table 2).
Hemodynamic variables, including cardiac index values
and the numbers of patients requiring vasoactive drugs or
inotropes, were not significantly different between the
groups throughout the study period (Table 3). There were
trends toward lower amounts of norepinephrine infused
(0.05  0.06 vs 0.03  0.05 mg/[kg $ min], P ¼ .072) and
fewer patients requiring norepinephrine doses greater than
0.05 mg/(kg $ min) (16 vs 9, P ¼ .087) at T3 in the RIPC
group relative to the control group. In intragroup compari-
sons of hemodynamic variables against baseline values,
heart rates at T2, T3, and T4 were significantly increased
in both groups. Mean arterial pressures at T2, mean pulmo-
nary arterial pressures at T3 and T4, and pulmonary capil-
lary wedge pressures at T3 and T4 were significantly
decreased in both groups. Mean pulmonary arterial pressure
and pulmonary capillary wedge pressure were significantly
decreased at T2 in the control group. Central venous pres-
sure at T2 and cardiac index values at T2 and T4 were
significantly increased in the RIPC group.ery c July 2011
TABLE 1. Patient characteristics
Variable
Control
(n ¼ 38)
RIPC
(n ¼ 38)
P
value
Age (y)
Mean  SD 60  13 57  12 .389
>70 (no.) 7 (18%) 3 (8%) .175
Sex (male/female) 15:23 15:23 >.999
Body surface area
(m2, mean  SD)
1.6  0.2 1.7  0.1 .315
Diabetes (no.) 4 (11%) 1 (3%) .165
Hypertension (no.) 10 (26%) 8 (21%) .589
Atrial fibrillation (no.) 21 (55%) 25 (66%) .348
Left ventricular ejection
fraction (%, mean  SD)
60%  12% 63%  9% .357
Estimated glomerular filtration
rate (mL/[min $ 1.73 m2])
Mean  SD 78  16 79  16 .891
<60 (no.) 4 (11%) 4 (11%) >.999
Preoperative medications (no.)
Digoxin 18 (47%) 14 (37%) .353
ACE-I or ARB 18 (47%) 16 (42%) .645
Calcium-channel blocker 5 (13%) 7 (18%) .529
b-Blockers 6 (16%) 9 (24%) .387
Diuretics 25 (66%) 26 (68%) .807
Statins 4 (11%) 2 (5%) .674
NYHA functional class III or IV (no.) 8 (21%) 6 (16%) .554
EuroSCORE (mean  SD) 3.5  2.4 3.1  1.4 .368
RIPC, Remote ischemic preconditioning; ACE-I, angiotensin-converting enzyme in-
hibitor; ARB, angiotensin receptor blocker; NYHA, New York Heart Association.
TABLE 2. Operative details and perioperative fluid balance and
transfusion
Variable
Control
(n ¼ 38)
RIPC
(n ¼ 38)
P
value
Duration of aortic crossclamp
(min, mean  SD)
108  29 98  27 .122
Duration of cardiopulmonary bypass (min)
Mean  SD 145  42 132  34 .144
>180 (no.) 7 (18%) 5 (13%) .529
Procedures (no.)
Concomitant valve or CABG 7 (18%) 2 (5%) .153
Multiple valve surgery 21 (55%) 17 (45%) .359
Bentall procedure 2 (5%) 4 (11%) .674
Mitral valve replacement 4 (11%) 9 (24%) .128
Mitral valve reconstruction 3 (8%) 2 (5%) >.999
Previous cardiac surgery 11 (29%) 13 (34%) .622
Input and output during operation
Crystalloid (mL, mean  SD) 2290  1076 2130  1032 .528
Colloid (mL, mean  SD) 786  467 944  1179 .458
Urinary output (mL, mean  SD) 1239  609 1229  609 .943
PRBCs transfused
(units, mean  SD)
1.3  1.5 1.0  1.5 .358
Fluid input (mL, mean  SD)
At ICU 0–24 h 4205  892 4252  1094 .84
At ICU 24–48 h 2653  825 2441  1051 .347
Urinary output (mL, mean  SD)
At ICU 0–24 h 3134  688 3512  1063 .069
At ICU 24–48 h 2449 729 2745  1085 .306
PRBCs transfused (units, mean  SD)
At ICU 0–24 h 0.4  1.1 0.9  2.1 .205
At ICU 24–48 h 0.2  0.7 0.1  0.4 .512
RIPC, Remote ischemic preconditioning; CABG, coronary artery bypass grafting;
PRBCs, packed red blood cells; ICU, intensive care unit.
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MThere were no differences in Qs/Qt, PaO2/inspired
oxygen fraction ratio, and alveolar–arterial oxygen gradi-
ent between the groups during perioperative period. In in-
tragroup comparisons of respiratory variables against
baseline values, Qs/Qt values at T2 and alveolar–arterial
oxygen gradients at T2 were significantly increased in
both groups. PaO2/inspired oxygen fraction ratios at T2
and T3 were significantly decreased in both groups
(Table 3).
There were no significant differences in serum levels of
creatinine, cystatin C, or NGAL or in estimated glomerular
filtration rate between the groups throughout the study
period.Highest serum creatinine levelswere observedwithin
the first 3 postoperative days in all patients. Serum creatinine
levels were increased and estimated glomerular filtration
rates were decreased relative to their respective baseline
values at postoperative days 1 and 2 in both groups. Plasma
NGAL levelswere increased relative to their respective base-
line values after surgery throughout the postoperative period
in both groups. Intragroup comparisons of serum cystatin C
levels revealed no significant differences at all time points of
measurements in both groups relative to the respective base-
line values of each group. AKI occurred in 34% (n¼ 26) of
all patients, the incidences of AKI did not differ between the
groups, and none of the patients required hemodialysis
(Table 4). CK-MB was significantly lower at 24 hours afterThe Journal of Thoracic and Casurgery in the RIPC group than in the control group
(32.0  19.1 vs 23.4  9.1 ng/mL, P ¼ .017).
Postoperative stay in the ICU was significantly shorter in
the RIPC group than in the control group. The times to
extubation and postoperative hospitalizations were similar
between the groups (Table 5).
DISCUSSION
In this prospective, randomized trial addressing the renal
protective effects of lower limb RIPC in patients undergo-
ing complex valvular heart surgery, we could not observe
any beneficial effects in terms of serum biomarkers for renal
injury and AKI development. RIPC was however, associ-
ated with significantly lower CK-MB level at 24 hours after
surgery and with shorter stay in the ICU than in the control
group.
AKI after cardiac surgery is associated with a high mor-
tality and more complicated postoperative course. It occurs
in as many as 40% of all patients after cardiac surgery, de-
pending on the specific definition, with 1% to 3% requir-
ing renal replacement therapy.2,14,15 Despite advances in
CPB techniques, the incidence of AKI after cardiacrdiovascular Surgery c Volume 142, Number 1 151
TABLE 3. Hemodynamic and respiratory variables and numbers of
patients requiring vasoactive drugs
Variables T1 T2 T3 T4
Heart rate (beats/min, mean  SD)
Control 65  10 84  13* 83  10* 83  10*
RIPC 67  15 82  11* 80  10* 81  14*
Mean arterial pressure (mm Hg, mean  SD)
Control 76  10 66  8* 76  9 74  7
RIPC 80  11 67  9* 77  11 75  11
Mean pulmonary arterial pressure (mm Hg, mean  SD)
Control 25  7 22  3* 20  4* 18  5*
RIPC 23  6 22  6 19  4* 20  5*
Central venous pressure (mm Hg, mean  SD)
Control 10  2 10  2 9  2 8  3
RIPC 9  3 11  2* 8  2 8  3
Pulmonary capillary wedge pressure (mm Hg, mean  SD)
Control 19  6 16  2* 15  3* 13  4*
RIPC 18  5 16  2 15  3* 14  4*
Cardiac index (L/[min $ m2], mean  SD)
Control 2.5  0.6 3.0  0.7 2.9  0.5 3.2  0.7
RIPC 2.3  0.5 2.8  0.5* 2.6  0.6 3.1  0.5*
Pulmonary shunt fraction (%, mean  SD)
Control 13.4  6.6 38.6  12.5*
RIPC 12.9  11.5 34.0  25.6*
PaO2/FiO2 (mean  SD)
Control 456  102 354  128* 370  95* 406  190
RIPC 484  110 393  125* 371  89* 437  106
PAO2PaO2 (mm Hg, mean  SD)
Control 62  39 124  86* 105  78 82  84
RIPC 62  41 97  71* 105  66 52  41
Norepinephrine (no.)
Control 0 26 (68%) 14 (37%) 10 (26%)
RIPC 0 20 (53%) 10 (26%) 10 (26%)
Milrinone (no.)
Control 0 13 (34%) 16 (42%) 17 (45%)
RIPC 0 10 (26%) 19 (50%) 13 (34%)
T1, 15 minutes after tracheal intubation; T2, 15 minutes after sternum closure; T3, 12
hours after arrival at intensive care unit; T4, 24 hours after arrival at intensive care
unit; RIPC, remote ischemic preconditioning; FiO2, inspired oxygen fraction; PAO2
PaO2, alveolar–arterial oxygen gradient. *P<.05 versus baseline (T1) in each group.
TABLE 4. Changes in renal biomarkers
Variable
Control
(n ¼ 38)
RIPC
(n ¼ 38)
P
value
Acute kidney injury (no.) 12 (32) 14 (37) .688
Creatinine (mg/dL, mean  SD)
Baseline 0.92  0.17 0.91  0.16 .871
ICU arrival 0.87  0.19 0.90  0.24 .567
POD 1 1.07  0.24 1.19  0.38 .094
POD 2 1.11  0.27 1.10  0.35 .81
POD 3 0.99  0.26 0.98  0.31 .904
Maximum within POD 3 1.19  0.25 1.24  0.36 .444
Change from baseline (%) 31%  23% 37%  32% .36
Cystatin C (mg/L, mean  SD)
Baseline 0.86  0.23 0.84  0.18 .67
ICU arrival 0.96  0.21 0.96  0.20 .981
24 h after surgery 0.84  0.28 0.84  0.32 .958
48 h after surgery 0.91  0.32 0.88  0.34 .508
Maximum within 48 h 0.97  0.32 0.92  0.36 .357
Plasma neutrophil gelatinase–associated lipocalin (ng/mL, mean  SD)
Baseline 49.5  20.6 50.6  14.0 .595
ICU arrival 255.0  121.6 272.4  99.7 .548
24 h after surgery 224.8  110.2 240.1  138.0 .805
Estimated glomerular filtration rate (mL/[min $ 1.73 m2], mean  SD)
ICU arrival 84  18 82  20 .737
POD 1 67  17 62  20 .206
POD 2 65  18 68  22 .461
POD 3 74  22 77  22 .699
RIPC, Remote ischemic preconditioning; ICU, intensive care unit; POD, postopera-
tive day.
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Msurgery has remained unchanged or has even slightly
increased.16 Mortality among patients with AKI has de-
creased with time with advances in practices of dialysis
care, although it is unchanged in those with multiple organ
dysfunctions.16 Even minor postoperative increases in se-
rum creatinine from preoperative baseline are associated
with increases in duration of ICU stay and short-term mor-
tality.4,5 The incidence of AKI is affected not only by
preoperative renal function but also by age, insulin-
dependent diabetes, impaired left ventricular function,
congestive heart failure, and particular types of cardiac
surgery.1,3,17 Among various cardiac surgical procedures,
risk of postoperative AKI is increased with valvular heart
surgery, especially double aortic and mitral valve
surgery, mitral valve involved procedure, reoperation,
and concomitant coronary artery bypass grafting.2,3 In152 The Journal of Thoracic and Cardiovascular Surgthese complex valvular heart procedures requiring
prolonged CPB, various conditions including CPB-
induced activation of inflammatory pathways, decreased
renal perfusion, and production of emboli and nephrotox-
ins contribute to development of AKI. Recent evidences
suggest that avoidance of excessive hemodilution and
transfusion, appropriate fluid management, maintenance
of tight glucose control with insulin, and the use of pulsa-
tile flow were only potential renal protective therapies, and
no interventions have demonstrated conclusive efficacy for
the prevention of AKI.1,18,19
RIPC is a protective strategy whereby brief limb ische-
mia confers systemic protection against prolonged ischemia
in distant organs through either humoral mediators or the re-
cruitment of a neuronal pathway.6,7 Although most of the
previous studies addressing RIPC have focused on the
protection of organs undergoing direct ischemia–
reperfusion injury, such as the heart and lungs in cardiac
surgery with CPB and kidneys in aortic surgery, RIPC is
a systemic protective strategy.8,9,20,21 RIPC attenuates the
systemic inflammatory response through activation of
a favorable profile of gene transcription that is both anti-
inflammatory and antiapoptotic.22,23 RIPC modifies gene
expression involved in cytokine synthesis; leukocyte
chemotaxis, adhesion, migration, and exocytosis; innateery c July 2011
TABLE 5. Postoperative outcome data
Variable
Control
(n ¼ 38)
RIPC
(n ¼ 38)
P
value
Reoperation for bleeding (no.) 4 (11%) 1 (3%) .2
Reintubation (no.) 1 (3%) 0 .493
Time on ventilator (h, mean  SD) 18.9  14.9 16.8  9.4 .456
Intensive care unit stay (d, mean  SD) 3.4  1.4 2.7  0.7* .013
Postoperative hospital stay
(d, mean  SD)
12.0  6.1 11.1  3.4 .435
RIPC, Remote ischemic preconditioning. *P<.05 versus control group.
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Mimmunity signaling pathways; and apoptosis in human
beings within 15 minutes, and more so after 24 hours.22
In clinical studies, RIPC mitigated CPB-induced systemic
inflammatory response syndrome, as shown by the in-
creased variance of interleukin 10 levels and reduced vari-
ance of tumor necrosis factor a levels in cardiac
surgery.23 We therefore hypothesized that this systemic
anti-inflammatory suppression might reduce the severity
or development of CPB-associated renal injury because of
the multiple factors involved in the pathogenesis.22 RIPC’s
obvious advantages of noninvasive nature, absence of cost,
and ease of application without interrupting operation were
also considered more advantageous than other interventions
for clinical application.
In contrast to our expectation, RIPC did not attenuate
the increase in serum biomarkers of renal injury in this study,
although it was associatedwith increased early postoperative
urinary output with similar use of diuretics. In this study, we
assessed renal injury with plasma NGAL and serum cystatin
C, which have been reported as sensitive, specific, and highly
predictive early biomarkers for AKI,14,24,25 as well as serum
creatinine. Early postoperative measurement of plasma
NGAL has been reported to be valuable for identifying
AKI independent of preoperative renal function.24 Although
serumcreatinine has been used as a biomarker of diagnosis of
AKI in numerous clinical studies, serum creatinine is a late
indicator of AKI because it does not accurately depict renal
function until a steady state has been reached, taking several
days when about half of the renal function has already been
lost.22 In addition, serumcreatininemay be affected by oblig-
atory CPB-related volume expansion in patients undergoing
cardiac surgery, resulting in a fall in serum creatinine despite
the presence of significant renal injury.We therefore assessed
plasmaNGAL and serum cystatin C until 24 and 48 hours af-
ter the surgery, respectively, and serumcreatinine until hospi-
tal discharge. Still no benefits were observed. The duration of
ischemia, the area under ischemia, and number of cycles of
RIPC used in this study were almost maximal compared
with previous studies and thus should not have affected the
results.
RIPC did, however, reduce elevation of myocardial en-
zyme levels, which was our secondary end point, and a trend
was seen toward reduced postoperative vasopressor require-The Journal of Thoracic and Caments with significantly shortened duration of ICU stay.
Plausible causes for the observations of this trial may be
that RIPC is more effective in protecting organs enduring
direct and obvious ischemia–reperfusion insult, resulting
in organ damage associated with marked proinflammatory
and oxidative stress. RIPC has exerted cardiac and lung pro-
tective effects in several clinical studies with aortic cross-
clamping and has shown renal protective effects in major
vascular surgery or interventions without perfusion to the
kidneys.20,23,26 Differences in mechanisms involved in
cardiac and renal protection conferred by RIPC may also
have affected the difference between the heart and kidney
with respect to RIPC protection. RIPC showed a biphasic
pattern of protection. An early phase is believed to act
within a few minutes to 2 to 4 hours after RIPC and
mediated by opening of mitochondrial adenosine
triphosphate–sensitive potassium channels.22,27 Early
phase is independent of protein synthesis and continues
into a later phase. A delayed second window of protection
occurs at 24 to 72 hours and is probably the result of
modified gene expression and protein synthesis. The anti-
inflammatory gene responses were significantly downregu-
lated at 15 minutes after termination of RIPC and then
markedly amplified at 24 hours.22 Reduction of CK-MB
at 24 hours after surgery in the RIPC group in this study
may be attributable to the late phase effect of remote protec-
tion. Moreover, vasopressor requirement after CPB may
closely reflect increased systemic inflammatory response–
related vasoplegia. The results of this study thus seem to
demonstrate a certain clinical utility of RIPC for patients
undergoing complex valvular heart surgery despite the
lack of renal protective effect.
The limitations of this study are as follows. Although we
measured reliable biomarkers of renal injury, we did not
measure inflammatory mediators related to CPB. Thus we
could not delineate the association between the lack of renal
protective effect of RIPC and the individual degree of sys-
temic inflammatory response. Also, the numbers of patients
with diabetes and those undergoing reoperation for postop-
erative bleeding were higher in the control group, which
may have confounded the results even though the differ-
ences were not statistically significant. The number of
patients involved was determined on the basis of the postop-
erative serum creatinine levels to evaluate the effect of
RIPC on postoperative renal function, and thus this study
might be underpowered to detect the effect of RIPC on
the incidence of postoperative AKI.
In conclusion, RIPC mediated by transient lower limb
ischemia did not exert renal protective effects in patients un-
dergoing complex valvular heart surgery without preexist-
ing renal insufficiency. The beneficial effects of RIPC
seem to be more prominent in organs directly affected by
ischemia–reperfusion injury, as demonstrated by reduced
release of myocardial enzyme.rdiovascular Surgery c Volume 142, Number 1 153
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